Skip to content

Prospective Controlled Study on the Analgesic Efficacy of Liposomal Bupivacaine for Local Infiltration Anesthesia Following Laparoscopic Cholecystectomy

A Prospective Study on the Analgesic Effect of Liposomal Bupivacaine Local Infiltration Anesthesia After Laparoscopic Cholecystectomy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118174
Enrollment
Unknown
Registered
2026-02-03
Start date
2025-11-19
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholecystitis and Pain

Interventions

Group 2:General anesthesia and local infiltration of bupivacaine liposome at the incision site

Sponsors

Fuyang Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Eighty patients scheduled for elective laparoscopic cholecystectomy were selected, with ages ranging from 18 to 70 years old and no gender restrictions. 2. The American Society of Anesthesiologists classification (American Society of Anesthesiologists, ASA) I and II level;

Exclusion criteria

Exclusion criteria: 1. Severe cardiopulmonary conditions, such as advanced coronary artery disease and chronic obstructive pulmonary disease (COPD); 2. Accept postoperative patient-controlled analgesia (epidural or intravenous); 3. Mental and Psychological Disorders: Such as schizophrenia, depression, history of chronic analgesic medication use, alcohol abuse, opioid dependence, or individuals unable to comprehend the Visual Analogue Scale (VAS); 4. Allergy to bupivacaine liposome; 5. Body mass index (BMI) > 35 kg/m².

Design outcomes

Primary

MeasureTime frame
Visual Analogue Score;Postoperative tramadol dosage;

Secondary

MeasureTime frame
The 15-item Postoperative Quality of Recovery Score at 24 hours after surgery;Sufentanil dosage;Untoward effect;The healing condition of the incision;

Countries

China

Contacts

Public ContactWang Xunxun

Fuyang Cancer Hospital

1428909805@qq.com+86 153 9967 5370

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026